Physician profile
John Otho Marsh
NPI 1619997566
$11,969.19
in general payments reported to CMS, 2019-2025
43 companies · $1,484 in 2025
The $1,484 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,433 · 2020: $1,174 · 2021: $2,414 · 2022: $1,664 · 2023: $2,099 · 2024: $1,702 · 2025: $1,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,277 · Education: $7.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,277.21 |
| Education | $7.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,112.64 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,204.58 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,001.52 | 2021-2025 | |
| Lilly USA, LLC | $851.91 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $817.95 | 2019-2025 | |
| Amarin Pharma, INC. | $744.76 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $742.16 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $554.82 | 2019-2023 | Xarelto |
| Amgen INC. | $544.95 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $349.50 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2, Freestyle Copilot |
| Novartis Pharmaceuticals Corporation | $265.95 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $255.83 | 2022 | |
| Glaxosmithkline, LLC. | $228.26 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $223.57 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.15 | 2020-2025 | Jardiance |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $178.21 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $176.42 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $168.88 | 2019-2023 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $165.30 | 2022-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Ani Pharmaceuticals, INC. | $154.45 | 2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $137.16 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $127.57 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.33 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $100.91 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi Pasteur INC. | $73.37 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.77 | 2024-2025 | Caplyta |
| Esperion Therapeutics, INC. | $46.77 | 2021 | |
| Fidia Pharma USA INC. | $44.17 | 2021-2024 | Hyalgan |
| Bayer Healthcare Pharmaceuticals INC. | $43.81 | 2025 | |
| Bioventus LLC | $42.04 | 2023-2024 | Supartz Fx Sodium Hyaluronate, Supartz Fx Sodium Hyaluronate |
| Axsome Therapeutics, INC. | $34.32 | 2024 | Auvelity |
| Ironshore Pharmaceuticals INC. | $26.74 | 2019 | |
| Almatica Pharma LLC | $26.67 | 2021 | |
| Sanofi-Aventis U.S. LLC | $25.48 | 2019-2020 | |
| Ibsa Pharma INC. | $19.98 | 2021 | |
| Allergan, INC. | $19.55 | 2020 | |
| Dexcom, INC. | $19.41 | 2024 | Dexcom G6 Transmitter |
| Philips North America LLC | $17.05 | 2025 | Extended Holter |
| Horizon Therapeutics Plc | $15.59 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.58 | 2020 | |
| Eisai INC. | $13.52 | 2021 | |
| Collegium Pharmaceutical, INC. | $13.11 | 2022 | |
| Mylan Specialty L.P. | $12.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Marsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.